Pramlintide

Pramlintide Acetate (Amylin Analogue)

Evidence & Status

  • FDA Approved
  • Strong Human Evidence
  • Established

At a Glance

A synthetic analog of amylin — the hormone co-secreted with insulin by pancreatic beta cells — that helps regulate postprandial blood sugar through mechanisms distinct from insulin. FDA-approved as an adjunct to insulin therapy in both type 1 and type 2 diabetes.

Plain English

Researchers study Pramlintide because it replaces amylin, a hormone normally secreted alongside insulin that helps manage the sharp rise in blood sugar following meals. Scientists are interested in the complementary roles of insulin and amylin in postprandial glucose control — knowledge that Pramlintide has been instrumental in generating. Its effects — slowing gastric emptying, reducing glucagon release after meals, and promoting satiety — are mechanistically distinct from those of insulin, making it an important example of how multiple hormone systems work together to regulate blood sugar.

Overview

Pramlintide is a synthetic analogue of human amylin, a hormone co-secreted with insulin. The FDA-approved SYMLINPEN indication is adjunctive treatment in adults with type 1 or type 2 diabetes who use mealtime insulin and have not achieved desired glucose control despite optimal insulin therapy. Its labeled clinical use, dosing, insulin adjustment, contraindications, and safety warnings are controlled by the current product label.

Research Summary

SYMLINPEN is FDA-labeled as an adjunct to mealtime insulin in adults with type 1 or type 2 diabetes who have not achieved desired glucose control despite optimal insulin therapy. The label specifies distinct type 1 and type 2 initiation/titration schedules, a 50% reduction in mealtime insulin at initiation, and warnings for severe hypoglycemia; it is contraindicated in hypoglycemia unawareness and confirmed gastroparesis.

Research Areas

  • Postprandial glucose control
  • Amylin receptor pharmacology
  • Weight reduction T1D/T2D
  • Gastric motility
  • GLP-1 combination therapy

Safety & Risks

Serious Risks

  • Severe hypoglycemia — reduce mealtime insulin by 50% at initiation
  • Contraindicated in hypoglycemia unawareness
  • Gastroparesis exacerbation
  • Do not mix with insulin in same syringe

Reported Side Effects

  • Nausea is common and differs by population and titration context.
  • Vomiting
  • Anorexia
  • Headache
  • Injection site reactions
United States
FDA-approved (Symlin — prescription, T1D and T2D mealtime insulin adjunct)
United Kingdom
Current authorization status not established in this record
Australia
Current authorization status not established in this record
Canada
Current authorization status not established in this record

Citations & Sources